Global Methotrexate Drug Market TOC
Methotrexate Drugs Market size is estimated to cross USD 701.97 million by the end of 2031, witnessing around 2.9% CAGR during the forecast period, i.e., 2022 – 2031. In the year 2021, the industry size of methotrexate drugs was over USD 531.61 million. The demand for methotrexate drugs is owing to the increasing use of the drugs for various inflammatory diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, and lupus. About 60% of people with rheumatoid arthritis are presently taking methotrexate, which is the recommended first-line treatment for rheumatoid arthritis, according to the American College of Rheumatology.
Moreover, the rising prevalence of autoimmune diseases is driving the demand for methotrexate drugs across the globe. As manufacturers are focusing on innovating new drugs in order to reduce the challenges faced by patients.
|
Base Year |
2021 |
|
Forecast Year |
2022-2031 |
|
CAGR |
2.9% |
|
Base Year Market Size (2021) |
USD 531.61 Million |
|
Forecast Year Market Size (2031) |
USD 701.97 Million |
|
Regional Scope |
|
Growth Drivers
Challenges
Disease Type (Cancer, Autoimmune Diseases, Ectopic Pregnancy)
The cancer segment in the methotrexate drugs market is estimated to gain a significant revenue share over the projected time frame. By the end of 2031, the cancer segment is anticipated to garner the largest revenue of USD 337.80 million. The segment is further expected to grow at a CAGR of 3.2% during the forecast period. Methotrexate drugs slows down the growth of cancer cells. The growth of the segment is due to the rising incidence rates of various types of cancers across the globe. For instance, according to the National Cancer Institute, Prostate, lung, and colorectal cancers account for an estimated 43% of all cancers diagnosed in men in 2020. For women, the three most common cancers are colorectal, breast, and lung which accounted for an estimated 50% of all new cancer diagnoses in women in 2020. In addition, higher usage of methotrexate in cancer treatment than in arthritis or psoriasis is also a major factor catering to the segment’s growth in the market. It is the initial treatment administered to cancer patients and is also used in combination therapy. In Japan, methotrexate is administered as the first-line treatment for cancer.
End-User (Hospitals, Specialty Clinics, Home Healthcare)
Methotrexate drugs market from the hospital segment is expected to garner a significant share of USD 390.45 million due to the increasing influx of patients with target diseases. Methotrexate is a kind of chemotherapy, and it is a treatment for a variety of cancers. According to the National Library of Medicine, in the United States, an estimated 60,000 cancer patients with cancer are hospitalized each year for chemotherapy. As the number of patients seeking treatment at hospitals continues to rise, the segment is further expected to grow with the highest CAGR of 3.3% during the forecast period. Besides, specialty clinics are expected to grow at a significant growth rate.
Our in-depth analysis of the global methotrexate drugs market includes the following segments:
|
Dosage Form |
|
|
Drug Type |
|
|
Disease Type |
|
|
Route of Administration |
|
|
End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
North American Market Forecast
The North America methotrexate drugs market is projected to hold a significant market share and account for USD 288.57 million by the end of 2031. The demand for methotrexate drugs is propelling in the region due to its high adoption of innovative technologies, and higher healthcare expenditures. In addition, the immediate availability of methotrexate pharmacotherapy, growing research and development linked to methotrexate drugs, multiple cancer survivor campaigns, high rates of psoriasis and arthritis, and the accessibility of reimbursement policies are also expected to contribute to regional growth. Also, the rising number of products and drugs that have been approved by the authorities. For example, U.S. specialty pharmaceutical company Cumberland Pharmaceuticals Inc. announced the launch of her RediTrex injection in November 2020. RediTrex is a new prefilled syringe specifically designed for ease of Use and precise dosing for subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis.
APAC Market Statistics
The Asia-Pacific methotrexate drugs market is predicted to have notable growth during the forecasted timeframe. The demand for methotrexate drugs in the region is majorly due to the increasing awareness of different medical modalities. Moreover, there are surging number of female populations requiring a medical abortion in the Asia Pacific region.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The surge in the prevalence of rheumatoid arthritis and the increasing prevalence of cancer are the major factors driving the market growth.
Ans: The market is anticipated to attain a CAGR of 2.9% over the forecast period, i.e., 2022 – 2031.
Ans: The major players in the market are Pfizer Inc., Azurity Pharmaceuticals, Inc., Cumberland Pharmaceuticals Inc., Inc, Teva Pharmaceuticals USA, Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, and Others
Ans: The cancer segment is anticipated to garner the largest market size by the end of 2031 and display significant growth opportunities.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2031 and provide more business opportunities in the future.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?